Received: 2 August 2019
Accepted: 1 November 2019
First Online: 26 November 2019
Ethics approval and consent to participate
: All individuals in the technical concordance cohort and clinical cohort gave electronic informed consent to have their de-identified information and sample used in anonymized studies (Western Institutional Review Board, #20150716). This research study conformed to the principles of the Helsinki Declaration.
: All individuals in the technical concordance cohort and clinical cohort gave electronic informed consent that Color may author publications using non-aggregated, de-identified information, either on its own or in collaboration with academic or commercial third parties.
: JRH, CLN, and AYZ are currently employed by and have equity interest in Color Genomics. JRH has previously consulted for Twist Bioscience and Etalon Diagnostics. GM was previously employed at Color Genomics and Operator. JRH and GM report a patent application related to low coverage whole genome sequencing. SK is an employee of Verve Therapeutics and holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics. He is a member of the scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; he has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, and Medscape; he reports patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetic risk predictor (20190017119). AVK has served as a consultant for Color Genomics and reports a patent related to a genetic risk predictor (20190017119).